Humabs BioMed is a leading Swiss antibody therapeutics company that discovers and develops superior monoclonal antibodies directly derived from individuals whose immune system has successfully responded to major diseases. These "winner antibodies" have already passed natural selection by the immune system in response to disease and can easily be developed for standardized therapeutic use. The company currently focuses on infectious diseases, but also has selected antibodies against inflammatory diseases and cancer in the pipeline.

The company has closed four major licensing deals with top pharmaceutical companies. Two of these partnered programs are in clinical development.